BIIL 284 Reduces Neutrophil Numbers but Increases P. Aeruginosa Bacteremia and Inflammation in Mouse Lungs

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2013 Nov 5

PMID 24183915

Citations 31

Authors

Gerd Doring

Alessandra Bragonzi

Moira Paroni

Firdevs-Fatma Akturk

Cristina Cigana

Annika Schmidt

Deirdre Gilpin

Susanne Heyder

Torsten Born

Christina Smaczny

Martin Kohlhaufl

Thomas O F Wagner

Michael R Loebinger

Diana Bilton

Michael M Tunney

J Stuart Elborn

Gerald B Pier

Michael W Konstan

Martina Ulrich

Affiliations

Soon will be listed here.

Abstract

Background: A clinical study to investigate the leukotriene B(4) (LTB(4))-receptor antagonist BIIL 284 in cystic fibrosis (CF) patients was prematurely terminated due to a significantly increased risk of adverse pulmonary events. We aimed to establish the effect of BIIL284 in models of Pseudomonas aeruginosa lung infection, thereby contributing to a better understanding of what could have led to adverse pulmonary events in CF patients.

Methods: P. aeruginosa DNA in the blood of CF patients during and after acute pulmonary exacerbations and in stable patients with non-CF bronchiectasis (NCFB) and healthy individuals was assessed by PCR. The effect of BIIL 284 treatment was tested in an agar bead murine model of P. aeruginosa lung infection. Bacterial count and inflammation were evaluated in lung and other organs.

Results: Most CF patients (98%) and all patients with NCFB and healthy individuals had negative P. aeruginosa DNA in their blood. Similarly, the P. aeruginosa-infected mice showed bacterial counts in the lung but not in the blood or spleen. BIIL 284 treatment decreased pulmonary neutrophils and increased P. aeruginosa numbers in mouse lungs leading to significantly higher bacteremia rates and lung inflammation compared to placebo treated animals.

Conclusions: Decreased airway neutrophils induced lung proliferation and severe bacteremia in a murine model of P. aeruginosa lung infection. These data suggest that caution should be taken when administering anti-inflammatory compounds to patients with bacterial infections.

Citing Articles

Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.

Dartois V, Bonfield T, Boyce J, Daley C, Dick T, Gonzalez-Juarrero M Tuberculosis (Edinb). 2024; 147:102503.

PMID: 38729070 PMC: 11168888. DOI: 10.1016/j.tube.2024.102503.

MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant infection.

De M, Serpa G, Zuiker E, Hisert K, Liles W, Manicone A Front Cell Infect Microbiol. 2024; 14:1275940.

PMID: 38352056 PMC: 10861668. DOI: 10.3389/fcimb.2024.1275940.

Bacteriophage: A new therapeutic player to combat neutrophilic inflammation in chronic airway diseases.

Laucirica D, Stick S, Garratt L, Kicic A Front Med (Lausanne). 2023; 9:1069929.

PMID: 36590945 PMC: 9794625. DOI: 10.3389/fmed.2022.1069929.

New TMA (4,6,4'-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease.

Tupini C, Chilin A, Rossi A, De Fino I, Bragonzi A, DAversa E Int J Mol Sci. 2022; 23(22).

PMID: 36430961 PMC: 9699093. DOI: 10.3390/ijms232214483.

Pamoic acid is an inhibitor of HMGB1·CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia.

De Leo F, Rossi A, De Marchis F, Cigana C, Melessike M, Quilici G Mol Med. 2022; 28(1):108.

PMID: 36071400 PMC: 9449960. DOI: 10.1186/s10020-022-00535-z.

References

Bragonzi A, Worlitzsch D, Pier G, Timpert P, Ulrich M, Hentzer M . Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis. 2005; 192(3):410-9. PMC: 1317300. DOI: 10.1086/431516. View

Goss C, Burns J . Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4):360-7. PMC: 2092469. DOI: 10.1136/thx.2006.060889. View

Alten R, Gromnica-Ihle E, Pohl C, Emmerich J, Steffgen J, Roscher R . Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis. 2004; 63(2):170-6. PMC: 1754875. DOI: 10.1136/ard.2002.004499. View

Ehlers M . CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2000; 2(3):289-94. DOI: 10.1016/s1286-4579(00)00299-9. View

Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B . Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994; 331(10):637-42. DOI: 10.1056/NEJM199409083311003. View

Li Y, Karlin A, Loike J, Silverstein S . Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J Exp Med. 2004; 200(5):613-22. PMC: 2212745. DOI: 10.1084/jem.20040725. View

Doring G, Hoiby N . Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004; 3(2):67-91. DOI: 10.1016/j.jcf.2004.03.008. View

Serio K, Baker J, Ring W, Riddick C, Bigby T . Leukotriene B4 costimulates 5-lipoxygenase activity in neutrophils via increased 5-lipoxygenase translocation. Am J Physiol. 1997; 272(4 Pt 1):C1329-34. DOI: 10.1152/ajpcell.1997.272.4.C1329. View

Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S . Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151(2):134-9, 139.e1. DOI: 10.1016/j.jpeds.2007.03.006. View

10.

Birke F, Meade C, Anderskewitz R, Speck G, Jennewein H . In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001; 297(1):458-66. View

11.

Doring G, Flume P, Heijerman H, Elborn J . Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012; 11(6):461-79. DOI: 10.1016/j.jcf.2012.10.004. View

12.

Ford-Hutchinson A, Bray M, Doig M, Shipley M, Smith M . Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980; 286(5770):264-5. DOI: 10.1038/286264a0. View

13.

McCormick J, Mehta G, Olesen H, Viviani L, Macek Jr M, Mehta A . Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010; 375(9719):1007-13. DOI: 10.1016/S0140-6736(09)62161-9. View

14.

Koh A, Priebe G, Ray C, van Rooijen N, Pier G . Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun. 2009; 77(12):5300-10. PMC: 2786465. DOI: 10.1128/IAI.00501-09. View

15.

Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T . A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997; 387(6633):620-4. DOI: 10.1038/42506. View

16.

Tsai W, Hershenson M, Zhou Y, Sajjan U . Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res. 2009; 58(8):491-501. PMC: 4164971. DOI: 10.1007/s00011-009-0015-9. View

17.

Samuelsson B, Dahlen S, Lindgren J, Rouzer C, Serhan C . Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987; 237(4819):1171-6. DOI: 10.1126/science.2820055. View

18.

McLaughlin F, Matthews Jr W, Strieder D, Sullivan B, Taneja A, Murphy P . Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983; 147(3):559-67. DOI: 10.1093/infdis/147.3.559. View

19.

Driscoll K, Hassenbein D, Carter J, Poynter J, Asquith T, Grant R . Macrophage inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells and in rat lung after mineral dust exposure. Am J Respir Cell Mol Biol. 1993; 8(3):311-8. DOI: 10.1165/ajrcmb/8.3.311. View

20.

Back M, Bu D, Branstrom R, Sheikine Y, Yan Z, Hansson G . Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A. 2005; 102(48):17501-6. PMC: 1297663. DOI: 10.1073/pnas.0505845102. View